ResMed Surges 4.38% on $450M Volume (Ranked 241st) as Institutions Boost Holdings and Analysts Hike Targets

ResMed Inc. (RMD) surged 4.38% on August 4, with a trading volume of $450 million, ranking 241st in market activity. Institutional investors, including SGL Investment Advisors and Invesco Ltd., bolstered their stakes, while UBS and Dimensional Fund Advisors increased holdings by 28.6% and 9.8%, respectively. The company announced a quarterly dividend hike to $0.60 per share, up from $0.53, payable on September 18. Analysts from JPMorgan, Royal Bank of Canada, and UBS upgraded their ratings, with price targets ranging from $290 to $325, reflecting confidence in its healthcare technology and respiratory care segments.

Insider transactions included CEO Michael Farrell selling 8,009 shares and Director Witte Jan De offloading 2,000 shares, reducing their holdings by 1.73% and 25.62%, respectively. Despite the insider sales, institutional ownership remains strong at 54.98%, indicating sustained institutional confidence. ResMed’s market cap currently stands at $40.88 billion, with a P/E ratio of 29.31 and a beta of 0.77, underscoring its defensive positioning in the healthcare sector.

The strategy of purchasing the top 500 stocks by daily trading volume and holding them for one day returned 166.71% from 2022 to the present, outperforming the benchmark by 137.53%. This highlights the impact of liquidity concentration and volatility on short-term performance, particularly for high-volume stocks like ResMed, where institutional and algorithmic trading activity can amplify price movements.